Effects of intensive induction and consolidation chemotherapy with idarubicin and high dose cytarabine on minimal residual disease levels in newly diagnosed adult precursor-B acute lymphoblastic leukemia
Kenneth F Bradstock, Alec Morley, Karen Byth, Jeff Szer, Ian Prosser, Paul Cannell, Ian Irving, John F Seymour
Contemporary Clinical Trials Communications | ELSEVIER INC | Published : 2016
We are grateful to Prof Lynda Campbell for interpretation of cytogenetic analyses on patients in this study, and to Dr Marnie Collins for statistical advice and assistance. We acknowledge the following physicians who contributed patients to the study: AnneMarie Watson, Townsville Hospital; Max Wolf, Miles Prince, Peter MacCallum Cancer Institute; Andrew Grigg, Royal Melbourne Hospital; David Gottlieb, Westmead Hospital; Robin Filshie, St Vincent's Hospital Melbourne. The study was partially supported by an unrestricted grant from Pharmacia Australia (now Pfizer Australia). The authors have no conflicts of interest to disclose.